Hospitals have plenty of AI to choose from. CARPL helps them decide what belongs in the reading room - and keeps watching after it gets there.
A vaginal swab, a molecular signal and a $45 million wager: PinkDx wants to help doctors rule out endometrial cancer before women endure an invasive workup.
Radiology has plenty of algorithms. CARPL sells the less glamorous thing hospitals need first: a way to choose, connect and keep watch over them.
A surgeon’s venture studio is tackling the awkward stretch between a promising healthcare product and a hospital that will actually use it. Its India market programme even makes room for a useful answer: no.
The Australian nonprofit helps digital health founders turn promising technology into something customers can buy and investors can back. Its bargain: specialist advice, milestone-based funding and some uncomfortable questions.
Deerfield Catalyst pairs veteran device inventors with a healthcare investor to test clinical ideas before the costly part begins. Its product is not one gadget - it is a repeatable way to turn a need into a company.
Arcade Therapeutics is a New York-based digital therapeutics company that builds clinically validated mobile games to treat mental illness. Founded by healthcare entrepreneur Raj Amin and neuroscientist Tracy Dennis-Tiwary, the company embeds a research-backed technique called attention bias modification into engaging games, starting with StarStarter for anxiety. Its lead prescription product, ABM-01, is pursuing FDA submission as one of the first game-based treatments for social anxiety disorder, with a pipeline extending to depression, addiction, and other conditions.
Hello Heart is a Menlo Park-based digital health company exclusively focused on cardiovascular health. Founded in 2013, it offers an AI-powered mobile app paired with a connected blood pressure monitor and smart pill box that helps members understand, track, and improve their heart health. Deployed through employers, health plans, and Medicare Advantage programs, Hello Heart has served users at 150+ Fortune 500 companies and government organizations. Independent peer-reviewed studies - including a JAMA study of 28,000+ participants - show that 84% of high-risk users reduced blood pressure over three years, with average medical cost savings exceeding $1,700 per enrolled member per year. The company has raised $148.5 million in total funding, most recently a $70 million Series D in May 2022.